basics of clinical research
DESCRIPTION
A basic powerpoint presentation to help freshers or interested folks understand what is clinical research all aboutTRANSCRIPT
![Page 1: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/1.jpg)
Mr.Siva Kartheek Matam M.PharmPatient Safety SpecialistMumbai
![Page 2: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/2.jpg)
Any research conducted on humans with ethical values to show that a device, drug, or treatment method is safe and effective.
It is a process of taking a new drug molecule in to the market through the regulatory approvals.
![Page 3: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/3.jpg)
1937 – Elixir Sulfanilamide disaster
105 US citizens died after treatment with sulfanilamide elixir containing diethylene glycol (DEG)
The incident hastened final enactment in 1938 of the Federal Food, Drug and Cosmetic Act
![Page 4: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/4.jpg)
1950’s - Thalidomide tragedy
Prescribed for controlling nausea and vomiting in pregnant women
Teratogenic – children born with deformed limbs.
1962 – Ban of thalidomide use in pregnant women.
![Page 5: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/5.jpg)
![Page 6: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/6.jpg)
PHASE I: Objective:
Objective of Phase 1 studies is to determine the maximum-tolerated dose with well-defined potential toxicities Initial assessment of safety, drug tolerability, and dose range in humans To study pharmacokinetic and pharmacodynamic parameters of the drug in human beings Healthy volunteers Small subject population (20-80)
![Page 7: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/7.jpg)
PHASE II: Objective:
Objective of Phase 2 Studies is to define the dose regimen of the drug that elicits the desired therapeutic benefit and that outweighs the observed clinical risks
Initial assessment of efficacy (proof-of-concept) and further assessment of safety
Involve patients who have the indicated disease or condition
Small patient population (100-300)
![Page 8: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/8.jpg)
PHASE III: Objective:
To provide sufficient data to convince the regulatory authorities of the favourable benefit/risk ratio of the drug under investigation
Large-scale studies aimed at verifying efficacy establishing safety, and establishing the optimum dosage
Phase-3 studies also called as confirmatory studies
Involve a larger number of patients (1000-3000)
![Page 9: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/9.jpg)
Protocol Investigator’s Brochure (IB) Form 1572 (FDA) – Statement by
Investigator Undertaking by Investigator (CDSCO –
ScheduleY) Financial Disclosure form Ethical Committee approval Directorate General for Foreign Trade
(DGFT) approval
![Page 10: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/10.jpg)
Informed Consent Form (ICF) Source Documents Case Report Form (CRF) Serious Adverse Event (SAE) Reporting
form Investigator Trial File (ITF) Correspondence file
![Page 11: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/11.jpg)
Filing NDA
(New Drug Applications) at
FDA
![Page 12: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/12.jpg)
POST MARKETING SURVEILLANCE (PMS): Objective:
To assess the long term effects of the drug
To determine drug behavior in huge patient pool
To determine new therapeutic benefits or indications
Regulatory requirement: Structured Adverse Events reporting system Periodic Safety Update Reports (PSURs)
![Page 13: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/13.jpg)
The PSURs are required to be submitted to DCGI – Once in every six months for the first two
years of the drug approval
Yearly once for the next two years
Then to be submitted annually.
![Page 14: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/14.jpg)
The Periodic Safety Update Report (PSUR) is required as part of the FDA Post Marketing Drug Risk Assessment (PMDRA) program.
USFDA-quarterly reports during first 3 years, then annual reports
EMEA - Report should be submitted every 6 months for first 2 years, annually for next three years and then five yearly after the first renewal
![Page 15: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/15.jpg)
Country: India Authority: Central Drug Standard
Control Organization (CDSCO) Head: Drug controller general of India
(DCGI)
![Page 16: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/16.jpg)
The CDSCO, headed by the DCGI, is primarily responsible for coordinating the activities of the State Drugs Control Organization, formulating policies and ensuring uniform implementation of the Drugs and Cosmetics Act of 1940 (DC Act) and the Drugs and Cosmetics Rules of 1945 (DC Rules) throughout India.
Schedule Y: The legislative requirements of pharmacovigilance in India are guided by specifications of Schedule Y.
![Page 17: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/17.jpg)
United States of America Authority: United States Food and Drug
administration (USFDA)
United Kingdom Authority: Medicines and Healthcare
products Regulatory Agency (MHRA)
![Page 18: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/18.jpg)
European countries Authority: Evaluation agency for
European medicines (or) European medicines evaluation agency (EMEA)
Australia Authority: Therapeutic Goods
Administration (TGA)
![Page 19: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/19.jpg)
Country: Canada Authority: Health Canada
![Page 20: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/20.jpg)
PharmaMedical
Statistician
StatisticianOther
LifeSciences
TherapeuticsGuidelines
AndRegulations
![Page 21: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/21.jpg)
Clinical Research Coordinator (CRC) or Clinical Trial Assistant (CTA)
Clinical Research Associate (CRA) Pharmacovigilance Specialist Clinical Data Associate Medical coder Medical Writer Regulatory Affairs or Medical Affairs Associate Literature Expert Medical Adviser or Medical Monitor (Medical
background) Biostatistician
JOB PROFILES
![Page 22: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/22.jpg)
Questions???
![Page 23: Basics of Clinical Research](https://reader031.vdocument.in/reader031/viewer/2022020421/568bf3d81a28ab89339bc94a/html5/thumbnails/23.jpg)
Thank You